{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:24:52Z","timestamp":1779416692496,"version":"3.53.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373169"],"award-info":[{"award-number":["82373169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972389"],"award-info":[{"award-number":["81972389"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102547","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:31:46Z","timestamp":1773750706000},"page":"102547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence on Preoperative Targeted Therapy for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus"],"prefix":"10.1016","volume":"24","author":[{"given":"Yaohui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyou","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102547_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA"},{"key":"10.1016\/j.clgc.2026.102547_bib0002","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.eururo.2007.05.009","article-title":"A critical analysis of surgery for kidney cancer with vena cava invasion","volume":"52","author":"Kirkali","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European association of urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2004.04897.x","article-title":"The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus","volume":"94","author":"Blute","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102547_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0006","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41392-024-01990-2","article-title":"Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduc Target Ther"},{"key":"10.1016\/j.clgc.2026.102547_bib0009","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2011.02.032","article-title":"The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus","volume":"59","author":"Cost","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0010","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2147\/OTT.S158114","article-title":"Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus","volume":"11","author":"Peng","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.clgc.2026.102547_bib0011","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrurol.2009.84","article-title":"Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib","volume":"6","author":"Harshman","year":"2009","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000296301","article-title":"Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects","volume":"84","author":"Kroeger","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2026.102547_bib0013","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jjco\/hyu014","article-title":"Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma","volume":"44","author":"Sassa","year":"2014","journal-title":"Japan J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ucl.2016.12.014","article-title":"Neoadjuvant targeted molecular therapy before renal surgery","volume":"44","author":"Dey","year":"2017","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2026.102547_bib0015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1442-2042.2012.03065.x","article-title":"Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?","volume":"19","author":"Schrader","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008475","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2026.102547_bib0017","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jvsv.2016.12.011","article-title":"Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma","volume":"5","author":"Haidar","year":"2017","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.clgc.2026.102547_bib0018","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2014.12.011","article-title":"Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma","volume":"68","author":"Shao","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110491","article-title":"Histopathology and outcomes of non-metastatic renal cell carcinoma with inferior vena cava tumor thrombus: systematic review and meta-analysis","volume":"51","author":"Lasorsa","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10147-017-1119-9","article-title":"Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma","volume":"22","author":"Fukuda","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0021","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00345-013-1088-1","article-title":"Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?","volume":"32","author":"Bigot","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0022","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","article-title":"A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)","volume":"127","author":"Stewart","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2026.102547_bib0023","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-016-3016-4","article-title":"Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2026.102547_bib0025","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clgc.2026.102547_bib0027","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0028","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/s41598-025-86712-6","article-title":"Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2026.102547_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104316","article-title":"Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: a systematic review and meta-analysis","volume":"196","author":"Gu","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2026.102547_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.euo.2023.06.006","article-title":"Prognostic significance of grade discrepancy between primary tumor and venous thrombus in nonmetastatic clear-cell renal cell carcinoma: analysis of the REMEMBER registry and implications for adjuvant therapy","volume":"7","author":"Wu","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0031","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jnci\/djt310","article-title":"An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma","volume":"105","author":"Hakimi","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2026.102547_bib0032","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2022.04.032","article-title":"Obesity in relation to renal cell carcinoma incidence and survival in three prospective studies","volume":"82","author":"Graff","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102547_bib0033","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102547_bib0034","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/1078-0432.CCR-21-1688","article-title":"Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN renal 101 trial","volume":"28","author":"Bilen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102547_bib0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40425-018-0425-8","article-title":"Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab","volume":"6","author":"Zahoor","year":"2018","journal-title":"J Immunother Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:36:29Z","timestamp":1779413789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000479"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102547","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Evidence on Preoperative Targeted Therapy for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102547"}}